-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic disease is the general term for diseases that do not constitute infection and have long-term accumulation of disease form damage.
Common chronic diseases mainly include cardiovascular and cerebrovascular diseases, cancer, diabetes, and chronic respiratory diseases
.
According to the "Report on the Status of Nutrition and Chronic Diseases of Chinese Residents (2020)", the base of patients with chronic diseases in China is expanding
.
With the continuous increase in the number of chronic disease users in China, the promotion of major chronic disease prevention and control has also been included in the "Healthy China 2030" Planning Outline
.
The industry believes that the chronic disease drug market will show huge room for growth under the background that the main treatment for chronic diseases is long-term medication and the number of patients continues to increase
.
It is reported that in the "White Paper on China's Internet Chronic Disease Management 2020", it pointed out that the market potential of China's Internet chronic disease management outside public hospitals is huge, and the market size is expected to exceed 230 billion yuan in 2025
.
At present, with the strong support of policies and the continuous expansion of the chronic disease drug market, the number of pharmaceutical companies engaged in chronic disease services is increasing
.
Among them, it is worth noting that many pharmaceutical companies have chosen to cooperate with Internet platforms
.
For example, in the near future, many pharmaceutical companies have chosen to "hand in hand" with Internet medical companies to explore the field of chronic diseases together
.
For example, on November 6, at the 4th China International Import Expo, Hanhui Pharmaceutical signed a strategic cooperation agreement with Huiyi Tianxia
.
The two parties will integrate resources to jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality out-of-hospital health management closed loop for patients with chronic diseases
.
On the same day, Leo Pharmaceuticals (Shanghai) Co.
, Ltd.
also further deepened the existing strategic partnership with Huiyi World
.
On the same day, at the China International Import Expo, the two sides also formally held a cooperation launch ceremony to jointly promote the construction of an Internet specialist hospital for dermatology
.
On September 9, Chen Siying, head of AstraZeneca’s e-commerce business, led a team to visit Dingdang Kuaiyao, and signed a 2022 strategic cooperation agreement with Dingdang Kuaiyao at the scene
.
The two parties announced that they will carry out in-depth cooperation based on the advantages of Dingdang Kuaiyao's integrated online and offline "digital pharmacy" model, the digitalization of pharmaceutical services, and AstraZeneca's outstanding drug research and development capabilities and years of experience in the health business field
.
On the whole, in the field of chronic disease management, cooperation between pharmaceutical companies and Internet medical companies is becoming more and more common.
Especially in recent years, as new technologies continue to empower various medical industry chains, pharmaceutical companies are Innovate existing businesses through new technologies
.
The industry predicts that with the intensification of the aging problem and the promotion of a series of favorable policies, the future Internet chronic disease management will turn the industry into a promising business opportunity in the Chinese medical market
.
However, this also means that the competition on the Internet + chronic disease management track will become increasingly fierce in the future
.
In this context, it is expected that in the future, companies that have their own medical resources and the ability to integrate and dispatch medical resources and require their own platform discipline construction capabilities may usher in more development opportunities
.
Common chronic diseases mainly include cardiovascular and cerebrovascular diseases, cancer, diabetes, and chronic respiratory diseases
.
According to the "Report on the Status of Nutrition and Chronic Diseases of Chinese Residents (2020)", the base of patients with chronic diseases in China is expanding
.
With the continuous increase in the number of chronic disease users in China, the promotion of major chronic disease prevention and control has also been included in the "Healthy China 2030" Planning Outline
.
The industry believes that the chronic disease drug market will show huge room for growth under the background that the main treatment for chronic diseases is long-term medication and the number of patients continues to increase
.
It is reported that in the "White Paper on China's Internet Chronic Disease Management 2020", it pointed out that the market potential of China's Internet chronic disease management outside public hospitals is huge, and the market size is expected to exceed 230 billion yuan in 2025
.
At present, with the strong support of policies and the continuous expansion of the chronic disease drug market, the number of pharmaceutical companies engaged in chronic disease services is increasing
.
Among them, it is worth noting that many pharmaceutical companies have chosen to cooperate with Internet platforms
.
For example, in the near future, many pharmaceutical companies have chosen to "hand in hand" with Internet medical companies to explore the field of chronic diseases together
.
For example, on November 6, at the 4th China International Import Expo, Hanhui Pharmaceutical signed a strategic cooperation agreement with Huiyi Tianxia
.
The two parties will integrate resources to jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality out-of-hospital health management closed loop for patients with chronic diseases
.
On the same day, Leo Pharmaceuticals (Shanghai) Co.
, Ltd.
also further deepened the existing strategic partnership with Huiyi World
.
On the same day, at the China International Import Expo, the two sides also formally held a cooperation launch ceremony to jointly promote the construction of an Internet specialist hospital for dermatology
.
On September 9, Chen Siying, head of AstraZeneca’s e-commerce business, led a team to visit Dingdang Kuaiyao, and signed a 2022 strategic cooperation agreement with Dingdang Kuaiyao at the scene
.
The two parties announced that they will carry out in-depth cooperation based on the advantages of Dingdang Kuaiyao's integrated online and offline "digital pharmacy" model, the digitalization of pharmaceutical services, and AstraZeneca's outstanding drug research and development capabilities and years of experience in the health business field
.
On the whole, in the field of chronic disease management, cooperation between pharmaceutical companies and Internet medical companies is becoming more and more common.
Especially in recent years, as new technologies continue to empower various medical industry chains, pharmaceutical companies are Innovate existing businesses through new technologies
.
The industry predicts that with the intensification of the aging problem and the promotion of a series of favorable policies, the future Internet chronic disease management will turn the industry into a promising business opportunity in the Chinese medical market
.
However, this also means that the competition on the Internet + chronic disease management track will become increasingly fierce in the future
.
In this context, it is expected that in the future, companies that have their own medical resources and the ability to integrate and dispatch medical resources and require their own platform discipline construction capabilities may usher in more development opportunities
.
